2025 Q4 -tulosraportti
16 päivää sitten
‧56 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·19.2.DNB is really "showing off" today and significantly raises the target price: "DNB Carnegie raises the target price for Hansa Biopharma to 35 kronor (33), reiterates hold" HC Wainwright, however, the other day lowers the target price for Hansa Biopharma to 103 kronor (111), reiterates buy.
·20.2. · MuokattuThere are clearly shorters who are counting on a large capital increase and possibly a delayed or "missed" approval in the USA. HCW then believes that it will continue to run by the book and that we will have a US approval in 2026/2027 - hope HCW is right - otherwise the 2027 ski trip is screwed. Would like to see some kind of deal with something upfront, which could eliminate the risk of a capital increase. Even if it doesn't end with a capital increase, more loans would also be annoying - we need to become CashFlow positive - it's currently probably mostly the enormous burnrate that makes some people uncertain - and that's with good reason.·20.2.Of course, it would be nice if we avoid loans or capital increases, which, of course, take a part of our expected return on our investment. But I don't fear it so much in Hansa, which has good experience with directed issues to external investors. Last time, as far as I remember, at a price of 39.
·19.2. · Muokattuhas uncertainty been created by the insider selling of 5,7 mill. yesterday is that why people want out insiders they know something more than us others I have bought a few more today at 33,98 for info I have it in 4 accounts in danske bank- ·19.2. · MuokattuQuite a ride up and down today. The last part a bit strange. Hansa has now received OK that the FDA will start evaluating the application. That's good news, because a timeline comes with it. But it's not smart that someone calls a sale the other day an insider sale from a board member. It was not. Read the press release - and also feel free to read my comment on it further down the page.
·19.2.But wasn't it stated in the article that it was a close friend of someone from the board of directors? That has certainly made me worried.·19.2.An employee in the same company as a board member in Hansa. If all colleagues are by definition insiders, then an incredible number of trades would have to be reported every day. So perhaps it's a bit far-fetched to call it an insider sale, unless they share a bedroom (and we don't know anything about that.) But the fact is that the press release affected you, even though the man (the seller) of course must not trade if he had any insider knowledge that was significant for his decision to sell. But OK, one can understand if the seller, who is a lawyer, wants to protect himself against accusations of potential insider knowledge, and perhaps it is even a requirement from the supervisory authorities. The närstående personen i fråga who is registered is Devin Holden, who is compliance manager at Novaquest... "HANSA BIOPHARMA: NÄRSTÅENDE TILL LEDAMOT SÅLT 141.000 AKTIER Close i dag kl. 06:43 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) En närståenderegistrerad person till Hansa Biopharmas styrelseledamot Michael Bologna har sålt drygt 141.000 aktier i bolaget för närmare 5,7 miljoner kronor. Det framgår av Finansinspektionens insynsregister. Michael Bologna är investeringschef på Novaquest Capital Management och den närstående personen i fråga som registrerat affären i Hansa Biopharma är Devin Holden, som enligt Novaquests hemsida är compliance-chef. Novaquest Capital Management är Hansa Biopharma's tredje största ägare med drygt 6 procent av kapital och röster, enligt ägardatatjänsten Holdings." - ·19.2.Luckily, I just barely managed to buy 1,500 at 36.78 - good thing I was quick at the keyboard this morning !!!! :-( - I understand nothing - but the market dictates, after all - so I was just wrong (again) !·19.2. · MuokattuSomeone might, in their haste, have made a mistake and thought that the approval of Imlifidase had been granted, and not noticed that for now, only the application has been approved. And perhaps they were just as rushed to get out again. Today's news is, after all, positive. And it doesn't help, for example, to call a sale the other day an insider sale from a board member. It was not.·19.2.I had actually expected that the report + that the FDA was satisfied with the application and is now starting to process the application would be enough for a little positive momentum. But I was obviously wrong there - one apparently waits for final approval before believing there's a business in imlifidase
- ·19.2.what the hell is going on here there's someone who WILL push the price down at any cost every time it reaches approx. price 40 it gets bombed down again even on good news what is that due to it's not heavily shorted anymore approx. 4.4 %·19.2. · MuokattuUh yes - short sellers !?. There's nothing strange about that - the short sellers simply believe that the price is far too high, so they borrow and sell, and expect to be able to get them cheaper at some point. Find it difficult to see long-term investors selling out on the news we've seen recently. Alternatively, that some of those who bought below 30 now want out when it hits around 36-40? We'll have to see if the short sellers have increased at the next disclosure of the short interest. Of course, there's no one who WANTS to keep it down and buys up to 40 only to constantly sell at 36!!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
16 päivää sitten
‧56 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·19.2.DNB is really "showing off" today and significantly raises the target price: "DNB Carnegie raises the target price for Hansa Biopharma to 35 kronor (33), reiterates hold" HC Wainwright, however, the other day lowers the target price for Hansa Biopharma to 103 kronor (111), reiterates buy.·20.2. · MuokattuThere are clearly shorters who are counting on a large capital increase and possibly a delayed or "missed" approval in the USA. HCW then believes that it will continue to run by the book and that we will have a US approval in 2026/2027 - hope HCW is right - otherwise the 2027 ski trip is screwed. Would like to see some kind of deal with something upfront, which could eliminate the risk of a capital increase. Even if it doesn't end with a capital increase, more loans would also be annoying - we need to become CashFlow positive - it's currently probably mostly the enormous burnrate that makes some people uncertain - and that's with good reason.·20.2.Of course, it would be nice if we avoid loans or capital increases, which, of course, take a part of our expected return on our investment. But I don't fear it so much in Hansa, which has good experience with directed issues to external investors. Last time, as far as I remember, at a price of 39.
- ·19.2. · Muokattuhas uncertainty been created by the insider selling of 5,7 mill. yesterday is that why people want out insiders they know something more than us others I have bought a few more today at 33,98 for info I have it in 4 accounts in danske bank
- ·19.2. · MuokattuQuite a ride up and down today. The last part a bit strange. Hansa has now received OK that the FDA will start evaluating the application. That's good news, because a timeline comes with it. But it's not smart that someone calls a sale the other day an insider sale from a board member. It was not. Read the press release - and also feel free to read my comment on it further down the page.·19.2.But wasn't it stated in the article that it was a close friend of someone from the board of directors? That has certainly made me worried.·19.2.An employee in the same company as a board member in Hansa. If all colleagues are by definition insiders, then an incredible number of trades would have to be reported every day. So perhaps it's a bit far-fetched to call it an insider sale, unless they share a bedroom (and we don't know anything about that.) But the fact is that the press release affected you, even though the man (the seller) of course must not trade if he had any insider knowledge that was significant for his decision to sell. But OK, one can understand if the seller, who is a lawyer, wants to protect himself against accusations of potential insider knowledge, and perhaps it is even a requirement from the supervisory authorities. The närstående personen i fråga who is registered is Devin Holden, who is compliance manager at Novaquest... "HANSA BIOPHARMA: NÄRSTÅENDE TILL LEDAMOT SÅLT 141.000 AKTIER Close i dag kl. 06:43 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) En närståenderegistrerad person till Hansa Biopharmas styrelseledamot Michael Bologna har sålt drygt 141.000 aktier i bolaget för närmare 5,7 miljoner kronor. Det framgår av Finansinspektionens insynsregister. Michael Bologna är investeringschef på Novaquest Capital Management och den närstående personen i fråga som registrerat affären i Hansa Biopharma är Devin Holden, som enligt Novaquests hemsida är compliance-chef. Novaquest Capital Management är Hansa Biopharma's tredje största ägare med drygt 6 procent av kapital och röster, enligt ägardatatjänsten Holdings."
- ·19.2.Luckily, I just barely managed to buy 1,500 at 36.78 - good thing I was quick at the keyboard this morning !!!! :-( - I understand nothing - but the market dictates, after all - so I was just wrong (again) !·19.2. · MuokattuSomeone might, in their haste, have made a mistake and thought that the approval of Imlifidase had been granted, and not noticed that for now, only the application has been approved. And perhaps they were just as rushed to get out again. Today's news is, after all, positive. And it doesn't help, for example, to call a sale the other day an insider sale from a board member. It was not.·19.2.I had actually expected that the report + that the FDA was satisfied with the application and is now starting to process the application would be enough for a little positive momentum. But I was obviously wrong there - one apparently waits for final approval before believing there's a business in imlifidase
- ·19.2.what the hell is going on here there's someone who WILL push the price down at any cost every time it reaches approx. price 40 it gets bombed down again even on good news what is that due to it's not heavily shorted anymore approx. 4.4 %·19.2. · MuokattuUh yes - short sellers !?. There's nothing strange about that - the short sellers simply believe that the price is far too high, so they borrow and sell, and expect to be able to get them cheaper at some point. Find it difficult to see long-term investors selling out on the news we've seen recently. Alternatively, that some of those who bought below 30 now want out when it hits around 36-40? We'll have to see if the short sellers have increased at the next disclosure of the short interest. Of course, there's no one who WANTS to keep it down and buys up to 40 only to constantly sell at 36!!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 |
2025 Q4 -tulosraportti
16 päivää sitten
‧56 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·19.2.DNB is really "showing off" today and significantly raises the target price: "DNB Carnegie raises the target price for Hansa Biopharma to 35 kronor (33), reiterates hold" HC Wainwright, however, the other day lowers the target price for Hansa Biopharma to 103 kronor (111), reiterates buy.·20.2. · MuokattuThere are clearly shorters who are counting on a large capital increase and possibly a delayed or "missed" approval in the USA. HCW then believes that it will continue to run by the book and that we will have a US approval in 2026/2027 - hope HCW is right - otherwise the 2027 ski trip is screwed. Would like to see some kind of deal with something upfront, which could eliminate the risk of a capital increase. Even if it doesn't end with a capital increase, more loans would also be annoying - we need to become CashFlow positive - it's currently probably mostly the enormous burnrate that makes some people uncertain - and that's with good reason.·20.2.Of course, it would be nice if we avoid loans or capital increases, which, of course, take a part of our expected return on our investment. But I don't fear it so much in Hansa, which has good experience with directed issues to external investors. Last time, as far as I remember, at a price of 39.
- ·19.2. · Muokattuhas uncertainty been created by the insider selling of 5,7 mill. yesterday is that why people want out insiders they know something more than us others I have bought a few more today at 33,98 for info I have it in 4 accounts in danske bank
- ·19.2. · MuokattuQuite a ride up and down today. The last part a bit strange. Hansa has now received OK that the FDA will start evaluating the application. That's good news, because a timeline comes with it. But it's not smart that someone calls a sale the other day an insider sale from a board member. It was not. Read the press release - and also feel free to read my comment on it further down the page.·19.2.But wasn't it stated in the article that it was a close friend of someone from the board of directors? That has certainly made me worried.·19.2.An employee in the same company as a board member in Hansa. If all colleagues are by definition insiders, then an incredible number of trades would have to be reported every day. So perhaps it's a bit far-fetched to call it an insider sale, unless they share a bedroom (and we don't know anything about that.) But the fact is that the press release affected you, even though the man (the seller) of course must not trade if he had any insider knowledge that was significant for his decision to sell. But OK, one can understand if the seller, who is a lawyer, wants to protect himself against accusations of potential insider knowledge, and perhaps it is even a requirement from the supervisory authorities. The närstående personen i fråga who is registered is Devin Holden, who is compliance manager at Novaquest... "HANSA BIOPHARMA: NÄRSTÅENDE TILL LEDAMOT SÅLT 141.000 AKTIER Close i dag kl. 06:43 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) En närståenderegistrerad person till Hansa Biopharmas styrelseledamot Michael Bologna har sålt drygt 141.000 aktier i bolaget för närmare 5,7 miljoner kronor. Det framgår av Finansinspektionens insynsregister. Michael Bologna är investeringschef på Novaquest Capital Management och den närstående personen i fråga som registrerat affären i Hansa Biopharma är Devin Holden, som enligt Novaquests hemsida är compliance-chef. Novaquest Capital Management är Hansa Biopharma's tredje största ägare med drygt 6 procent av kapital och röster, enligt ägardatatjänsten Holdings."
- ·19.2.Luckily, I just barely managed to buy 1,500 at 36.78 - good thing I was quick at the keyboard this morning !!!! :-( - I understand nothing - but the market dictates, after all - so I was just wrong (again) !·19.2. · MuokattuSomeone might, in their haste, have made a mistake and thought that the approval of Imlifidase had been granted, and not noticed that for now, only the application has been approved. And perhaps they were just as rushed to get out again. Today's news is, after all, positive. And it doesn't help, for example, to call a sale the other day an insider sale from a board member. It was not.·19.2.I had actually expected that the report + that the FDA was satisfied with the application and is now starting to process the application would be enough for a little positive momentum. But I was obviously wrong there - one apparently waits for final approval before believing there's a business in imlifidase
- ·19.2.what the hell is going on here there's someone who WILL push the price down at any cost every time it reaches approx. price 40 it gets bombed down again even on good news what is that due to it's not heavily shorted anymore approx. 4.4 %·19.2. · MuokattuUh yes - short sellers !?. There's nothing strange about that - the short sellers simply believe that the price is far too high, so they borrow and sell, and expect to be able to get them cheaper at some point. Find it difficult to see long-term investors selling out on the news we've seen recently. Alternatively, that some of those who bought below 30 now want out when it hits around 36-40? We'll have to see if the short sellers have increased at the next disclosure of the short interest. Of course, there's no one who WANTS to keep it down and buys up to 40 only to constantly sell at 36!!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt